文献速递胸部肿瘤

纳武利尤单抗联合伊匹木单抗对比纳武利尤单抗治疗经治IV期鳞状细胞肺癌:Lung-MAP S1400I 3期随机临床试验

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

Lung-MAP S1400I 3期开放标签随机试验纳入经铂类化疗后进展、未接受过免疫治疗的晚期鳞状NSCLC患者,随机接受纳武利尤单抗联合伊匹木单抗或纳武利尤单抗单药。联合组≥3级治疗相关不良事件发生率39.5%,高于单药组33.3%。

要点

  • 在经治晚期鳞状NSCLC中,纳武利尤单抗联合伊匹木单抗未改善总生存。
  • 联合组中位OS 10个月,单药组11个月,差异无统计学意义。
  • 联合组≥3级治疗相关不良事件39.5%,因毒性停药25%。

核心结论

  • 在经治、未接受过免疫检查点抑制剂的晚期鳞状NSCLC患者中,纳武利尤单抗联合伊匹木单抗未改善结局。

研究设计与样本

  • Lung-MAP S1400I为3期开放标签随机临床试验,2015年12月18日至2018年4月23日入组,按1:1随机分配至纳武利尤单抗单药或联合伊匹木单抗。
  • 纳入经标准铂类化疗后进展、未接受过免疫治疗的晚期鳞状NSCLC患者,Zubrod评分0-1,按性别和既往治疗线数(1 vs ≥2)分层。
  • 275例入组患者中252例符合条件纳入分析(联合组125例,单药组127例),存活患者中位随访29.5个月。

主要发现

  • 联合组缓解率18%(95%CI 12%-25%),单药组17%(95%CI 10%-23%);联合组中位缓解持续时间28.4个月(95%CI 4.9个月至未达到),单药组9.7个月(95%CI 4.2-23.1)。

关键数值与推荐

  • 联合组≥3级治疗相关不良事件49/124例(39.5%),单药组41/123例(33.3%)。
  • 毒性导致停药:联合组31/124例(25%),单药组19/123例(15%)。
  • 研究在计划中期分析时因无效提前终止。

临床怎么用

  • 对于经铂类化疗后进展、未接受过免疫治疗的晚期鳞状NSCLC,不推荐在纳武利尤单抗基础上常规联合伊匹木单抗。
  • 联合方案未显示生存获益且毒性增加,临床决策应优先考虑单药免疫治疗。

局限性

  • 研究因无效提前终止,可能影响次要终点和亚组分析的统计效能。
  • 开放标签设计可能影响研究者评估的PFS等终点。
  • 入组人群以白人(82%)和男性(67%)为主,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Nivolumab plus ipilimumab is superior to platinum-based chemotherapy in treatment-naive advanced non-small cell lung cancer (NSCLC). Nivolumab is superior to docetaxel in advanced pretreated NSCLC. OBJECTIVE: To determine whether the addition of ipilimumab to nivolumab improves survival in patients with advanced, pretreated, immunotherapy-naive squamous (Sq) NSCLC. DESIGN, SETTING, AND PARTICIPANTS: The Lung Cancer Master Protocol (Lung-MAP) S1400I phase 3, open-label randomized clinical trial was conducted from December 18, 2015, to April 23, 2018, randomizing patients in a 1:1 ratio to nivolumab alone or combined with ipilimumab. The median follow-up in surviving patients was 29.5 months. The trial was conducted through the National Clinical Trials Network and included patients with advanced immunotherapy-naive SqNSCLC and a Zubrod score of 0 (asymptomatic) to 1 (symptomatic but completely ambulatory) with disease progression after standard platinum-based chemotherapy. Randomization was stratified by sex and number of prior therapies (1 vs 2 or more). Data were analyzed from May 3, 2018, to February 1, 2021. INTERVENTIONS: Nivolumab, 3 mg/kg intravenously every 2 weeks, with or without ipilimumab, 1 mg/kg intravenously every 6 weeks, until disease progression or intolerable toxic effects. MAIN OUTCOMES AND MEASURES: The primary end point was overall survival (OS). Secondary end points included investigator-assessed progression-free survival (IA-PFS) and response per Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, version 1.1. RESULTS: Of 275 enrolled patients, 252 (mean age, 67.5 years [range 41.8-90.3 years]; 169 men [67%]; 206 White patients [82%]) were deemed eligible (125 randomized to nivolumab/ipilimumab and 127 to nivolumab). The study was closed for futility at a planned interim analysis. Overall survival was not significantly different between the groups (hazard ratio [HR], 0.87; 95% CI, 0.66-1.16; P = .34). Median survival was 10 months (95% CI, 8.0-14.4 months) in the nivolumab/ipilimumab group and 11 months (95% CI, 8.6-13.7 months) in the nivolumab group. The IA-PFS HR was 0.80 (95% CI, 0.61-1.03; P = .09); median IA-PFS was 3.8 months (95% CI, 2.7-4.4 months) in the nivolumab/ipilimumab group and 2.9 months (95% CI, 1.8-4.0 months) in the nivolumab alone group. Response rates were 18% (95% CI, 12%-25%) with nivolumab/ipilimumab and 17% (95% CI, 10%-23%) with nivolumab. Median response duration was 28.4 months (95% CI, 4.9 months to not reached) with nivolumab/ipilimumab and 9.7 months with nivolumab (95% CI, 4.2-23.1 months). Grade 3 or higher treatment-related adverse events occurred in 49 of 124 patients (39.5%) who received nivolumab/ipilimumab and in 41 of 123 (33.3%) who received nivolumab alone. Toxic effects led to discontinuation in 31 of 124 patients (25%) on nivolumab/ipilimumab and in 19 of 123 (15%) on nivolumab. CONCLUSIONS AND RELEVANCE: In this phase 3 randomized clinical trial, ipilimumab added to nivolumab did not improve outcomes in patients with advanced, pretreated, immune checkpoint inhibitor-naive SqNSCLC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02785952.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Gettinger SN, Redman MW, Bazhenova L, et al. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 34264316. doi:10.1001/jamaoncol.2021.2209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。